Serum Leptin Levels in Patients Undergoing Carotid Endarterectomy: A Pilot Study

Angiology

Volumn 60, Issue 6, 2009, Pages 698-704

  Bountouris, Ioannis ^a   Paraskevas, Kosmas I ^a   Koutouzis, Michael ^b   Tzavara, Vassiliki ^a   Nikolaou, Nikolaos ^a   Nomikos, Alexandros ^a   Barbatis, Calypso ^a   Andrikopoulos, Vassilios ^a   Mikhailidis, Dimitri P ^c   Andrikopoulou, Maria ^a   Kyriakides, Zenon S ^a   Georgopoulos, Sotirios ^d   Michail, Panagiotis O ^d   Bastounis, Elias ^d  

^a RED CROSS HOSPITAL   (Greece)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

cardiovascular events; carotid artery disease; inflammation; leptin

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 6; LEPTIN;

AGED; ARTICLE; BLOOD; BODY MASS; CAROTID ARTERY DISEASE; CAROTID ENDARTERECTOMY; COMPARATIVE STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PHOTOMETRY; PILOT STUDY; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BODY MASS INDEX; CAROTID ARTERY DISEASES; DISEASE PROGRESSION; ENDARTERECTOMY, CAROTID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-6; LEPTIN; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PILOT PROJECTS; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 77449111370     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319709350133     Document Type: Article

References (33)

1. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normalweight and obese humans. N Engl J Med. 1996;334(5): 292-295.
2. Klein S, Coppack SW, Mohamed-Ali V, et al. Adipose tissue leptin production and plasma leptin kinetics in humans. Diabetes. 1996;45(7):984-987.
3. Paraskevas KI, Liapis CD, Mikhailidis DP. Leptin: a promising therapeutic target with pleiotropic action besides body weight regulation. Curr Drug Targets. 2006;7(6): 761-771.
4. Poulakou MV, Paraskevas KI, Wilson MR, et al. Apolipoprotein J and leptin levels in patients with coronary heart disease. In Vivo. 2008;22(4):537-542.
5. Fietta P. Focus on leptin, a pleiotropic hormone. Minerva Med. 2005;96(2):65-75.
6. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 2001;104(25):3052-3056.
7. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol. 2004;44(9):1819-1824.
8. Couillard C, Lamarche B, Mauriege P, et al. Leptinemia is not a risk factor for ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Diabetes Care. 1998;21(5):782-786.
9. Piemonti L, Calori G, Mercalli A, et al. Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes Care. 2003;26(10):2883-2889.
10. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92(5):1355-1374.
11. Beltowski J. Leptin and atherosclerosis. Atherosclerosis. 2006;189(1):47-60.
12. Norata GD, Raselli S, Grigore L, et al. Leptin:adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke. 2007; 38(10):2844-2846.
13. Ciccone M, Vettor R, Pannacciulli N, et al. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord. 2001;25(6):805-810.
14. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol. 2003;157(1):25-31.
15. Oflaz H, Ozbey N, Mantar F, et al. Determination of endothelial function and early atherosclerotic changes in healthy obese women. Diabetes Nutr Metab. 2003; 16(3):176-181.
16. Aust G, Richter O, Rohm S, et al. Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis. 2009;204(1):262-266.
17. Schneiderman J, Simon AJ, Schroeter MR, Flugelman MY, Konstantinides S, Schaefer K. Leptin receptor is elevated in carotid plaques from neurologically symptomatic patients and positively correlated with augmented macrophage density. J Vasc Surg. 2008; 48(5):1146-1155.
18. Jander S, Sitzer M, Schumann R, et al. Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaque destabilization. Stroke. 1998;29(8):1625-1630.
19. Husain T, Abbott CR, Scott DJ, Gough MJ. Macrophage accumulation within the cap of carotid atherosclerotic plaques is associated with the onset of cerebral ischemic events. J Vasc Surg. 1999;30(2):269-276.
20. Paraskevas KI, Hamilton G, Mikhailidis DP. Statins: an essential component in the management of carotid artery disease. J Vasc Surg. 2007;46(2):373-386.
21. Davis M, Atwal AS, Nair DR, et al. The effect of shortterm lipid lowering with atorvastatin on carotid artery intima media thickness in patients with peripheral vascular disease: a pilot study. Curr Med Res Opin. 2000; 16(3):198-204.
22. Youssef F, Seifalian AM, Jagroop IA, et al. The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). Eur J Vasc Endovasc Surg. 2002;23(4):358-364.
23. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin. 2003;19(6): 540-556.
24. Paraskevas KI, Mikhailidis DP. Anaesthetic techniques for carotid surgery. Lancet. 2009;373(9666):807.
25. Watanabe K, Sugiyama S, Kugiyama K, et al. Stabilization of carotid atheroma assessed by quantitative ultrasound analysis in nonhypercholesteroloemic patients with coronary artery disease. J Am Coll Cardiol. 2005; 46(11):2022-2030.
26. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation and plaque stability. Cardiovasc Res. 2000;47(4):648-657.
27. Gomez-Hernandez A, Sachez-Galan E, Martin-Ventura JL, et al. Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: potential implications for plaque stabilization. J Cardiovasc Pharmacol. 2006;47(1):60-69.
28. Kunte H, Amberger N, Busch MA, Rückert RI, Meiners S, Harms L. Markers of instability in high-risk carotid plaques are reduced by statins. J Vasc Surg. 2008;47(3):513-522.
29. Isma N, Barani J, Mattiasson L, Lindblad B, Gottsäter A. Lipid-lowering therapy is related to inflammatory markers and 3-year mortality in patients with critical limb ischemia. Angiology. 2008;59(5):542-548.
30. Toli K, Paraskevas KI, Poulakou MV, et al. Association between plasma levels and immunolocalization of cytokines in heart valve lesions: a possible target for treatment? Expert Opin Ther Targets. 2008;12(10):1209-1215.
31. Paraskevas KI, Tzovaras AA, Briana DD, Mikhailidis DP. Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr Pharm Des. 2007;13(35):3622-3636.
32. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des. 2009;15(5):479-489.
33. Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke. 2006;37(7):1923-1932.